OptimizeRx Upgraded to Buy Following Margin Expansion and Positive 2027 Outlook

Key Facts

1OptimizeRx was upgraded to 'Buy' based on an improved 2027 growth outlook and attractive valuation.

2The company's gross margin rose to 76.5% in Q2 2026, marking five consecutive quarters of gains.

3The company reaffirmed 2026 guidance with revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.

Amid a strategic shift in the healthcare technology sector toward operational efficiency, OptimizeRx (OPRX) has been upgraded to a 'Buy' rating. This upgrade is driven by an improved growth outlook for 2027 and what analysts describe as an attractive valuation. The company’s gross margin climbed to 76.5% in the second quarter of 2026, marking five consecutive quarters of margin expansion resulting from a pivot toward higher-margin service offerings.

Regarding its financial guidance, the company reaffirmed its full-year 2026 targets, projecting revenue between $95 million and $100 million. Additionally, adjusted EBITDA is expected to fall within the $21 million to $25 million range. This consistent performance in margin growth and reaffirmed outlook underscores the company's successful execution of its long-term profitability strategy according to analyst reports.

Per market data, OPRX closed at $7.59 on September 17, 2026, having traded between a low of $7.54 and a high of $7.72 during that session. Investors will be monitoring the sustainability of these margins against a broader economic backdrop; notably, US Super Core CPI was reported at 2.99% YoY on September 11, reflecting persistent inflationary pressures that may influence broader market sentiment for growth-oriented tech stocks.